BioVie to Present New Long COVID Biomarker Data at International Medical Conference
BioVie, a clinical-stage biotechnology company developing treatments for neurological and neurodegenerative diseases, has been invited to deliver a late-breaking oral presentation at the 4th Long COVID International Conference 2026, taking place November 12–13 in Nice, France. Dr. Penelope Markham, BioVie’s Senior Vice President and Program Lead for Long COVID, will present on Friday, November 13, sharing previously undisclosed biomarker data related to the company’s Long COVID research.
The presentation comes as Long COVID continues to affect millions of Americans, with an estimated 17–20 million U.S. adults living with the condition and approximately 3.8 million experiencing significant limitations in daily activities. BioVie’s upcoming presentation will provide an opportunity to share additional scientific findings with the international medical community as researchers continue investigating the condition and potential treatments.
#BioVie #LongCOVID #LongCOVIDResearch #Biomarkers #Biotechnology #Biotech #MedicalResearch #ClinicalResearch #Neurology #LongCOVIDConference #HealthcareInnovation #MedicalConference #PenelopeMarkham #JaneKing #NewsOut
